Findings

What do systematic reviews say?

2,543 questions · 2,589 findings · 168 reviews · Schizophrenia

Sort:Best matchNewestHighest certainty Download CSV

No studies found 601 · 23.2%GRADE not reported 446 · 17.2%Very low 721 · 27.8%Low 505 · 19.5%Moderate 274 · 10.6%High 42 · 1.6%

Cannabidiol vs AMISULPRIDE

Cannabis use · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabidiol vs AMISULPRIDE

Mental state: PANSS total (high = bad) ‐ medium term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabidiol vs AMISULPRIDE

Global state: relapse ‐ medium term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabidiol vs AMISULPRIDE

General functioning ‐ no clinically important change in general functioning · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabidiol vs AMISULPRIDE

Adverse effects: measured adverse events ‐ medium term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabidiol vs AMISULPRIDE

Leaving the study early ‐ medium term ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabidiol vs AMISULPRIDE

Satisfaction with treatment ‐ medium term ‐ not measured · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY vs treatment

Global state: relapse ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY vs treatment

Average change in quality of life/satisfaction · patients with SCHIZOPHRENIA AND CANNABIS USE

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Moderate

CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY vs treatment

Adverse effects: no clinically important adverse effects ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY vs treatment

Leaving the study early ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY vs treatment

Satisfaction with treatment ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION

Cannabis use · patients with SCHIZOPHRENIA AND CANNABIS USE

CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT… showed no clear difference in behaviour: Cannabis use: Used cannabis in last 4 weeks ‐ medium term… compared with NON‐SPECIFIC PSYCOEDUCTION (moderate certainty).

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.04 [0.62, 1.74]
1 study · 47 participants
Moderate

CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION

Mental state · patients with SCHIZOPHRENIA AND CANNABIS USE

1 finding from 1 review

Cannabis and schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Moderate

ACUPUNCTURE added to STANDARD DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS

Global state: Not improved, endpoint ‐ medium‐term (various similar criteria) · patients with schizophrenia

It is very uncertain whether ACUPUNCTURE added to STANDARD DOSE ANTIPSYCHOTICS changes global state: Not improved, endpoint ‐ medium‐term (various similar… compared with STANDARD DOSE ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.4 [0.28, 0.57]
3 studies · 244 participants
Very low

ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

It is very uncertain whether ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS changes behaviour: Leaving the study early (short‐term) compared with STANDARD DOSE ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.81 [0.29, 2.29]
8 studies · 662 participants
Very low

ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS

Service outcomes: Hospitalisation · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS

Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia

ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS may leads to lower adverse effects: Extrapyramidal symptoms ‐ specific ‐ akathisia… compared with STANDARD DOSE ANTIPSYCHOTICS (low certainty).

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.03 [0, 0.49]
1 study · 180 participants
Low

ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS

Quality of life: No clinically important change in quality of life · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS

Economic outcomes: Cost of care · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found